Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 14.93 USD 2.19%
Market Cap: $301.7m

P/E

-4.8
Current
107%
Cheaper
vs 3-y average of 72.2

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-4.8
=
Market Cap
$294.2m
/
Net Income
$-62.8m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-4.8
=
Market Cap
$294.2m
/
Net Income
$-62.8m

Valuation Scenarios

Simulations Plus Inc is trading above its 3-year average

If P/E returns to its 3-Year Average (72.2), the stock would be worth $-224.25 (1 602% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-1 738%
Maximum Upside
No Upside Scenarios
Average Downside
1 147%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -4.8 $14.93
0%
3-Year Average 72.2 $-224.25
-1 602%
5-Year Average 78.7 $-244.48
-1 738%
Industry Average 27.6 $-85.74
-674%
Country Average 22.9 $-71.06
-576%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
$294.2m
/
Mar 2026
$-62.8m
=
-4.8
Current
$294.2m
/
Aug 2026
$11m
=
26.7
Forward
$294.2m
/
Aug 2027
$11.3m
=
26.1
Forward
$294.2m
/
Aug 2028
$12.8m
=
22.9
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

All Countries
Close

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 8 489 companies
0th percentile
-4.8
Low
0 — 15.3
Typical Range
15.3 — 33.2
High
33.2 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.3
Median 22.9
70th Percentile 33.2
Max 1 826 183.3

Simulations Plus Inc
Glance View

Market Cap
301.7m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
14.39 USD
Overvaluation 4%
Intrinsic Value
Price $14.93
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett